BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 31524156)

  • 21. Plasma Apolipoprotein E3 and Glucose Levels Are Associated in APOE ɛ3/ɛ4 Carriers.
    Edlund AK; Chen K; Lee W; Protas H; Su Y; Reiman E; Caselli R; Nielsen HM
    J Alzheimers Dis; 2021; 81(1):339-354. PubMed ID: 33814450
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inflammation in Alzheimer's Disease: Do Sex and APOE Matter?
    Duarte-Guterman P; Albert AY; Inkster AM; Barha CK; Galea LAM;
    J Alzheimers Dis; 2020; 78(2):627-641. PubMed ID: 33016923
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In Thai Nationals, the ApoE4 Allele Affects Multiple Domains of Neuropsychological, Biobehavioral, and Social Functioning Thereby Contributing to Alzheimer's Disorder, while the ApoE3 Allele Protects Against Neuropsychiatric Symptoms and Psychosocial Deficits.
    Tangwongchai S; Supasitthumrong T; Hemrunroj S; Tunvirachaisakul C; Chuchuen P; Houngngam N; Snabboon T; Tawankanjanachot I; Likitchareon Y; Phanthumchindad K; Maes M
    Mol Neurobiol; 2018 Aug; 55(8):6449-6462. PubMed ID: 29307083
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CSF tau is associated with impaired cortical plasticity, cognitive decline and astrocyte survival only in APOE4-positive Alzheimer's disease.
    Koch G; Di Lorenzo F; Loizzo S; Motta C; Travaglione S; Baiula M; Rimondini R; Ponzo V; Bonnì S; Toniolo S; Sallustio F; Bozzali M; Caltagirone C; Campana G; Martorana A
    Sci Rep; 2017 Oct; 7(1):13728. PubMed ID: 29062035
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interplay between the APOE Genotype and Possible Plasma Biomarkers in Alzheimer's Disease.
    Zverova M; Kitzlerova E; Fisar Z; Jirak R; Hroudova J; Benakova H; Lelkova P; Martasek P; Raboch J
    Curr Alzheimer Res; 2018; 15(10):938-950. PubMed ID: 29852871
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Factors that influence the levels of cerebrospinal fluid biomarkers in memory clinic patients.
    Knapskog AB; Eldholm RS; Braekhus A; Engedal K; Saltvedt I
    BMC Geriatr; 2017 Sep; 17(1):210. PubMed ID: 28893185
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CSF cutoffs for MCI due to AD depend on APOEε4 carrier status.
    Marizzoni M; Ferrari C; Babiloni C; Albani D; Barkhof F; Cavaliere L; Didic M; Forloni G; Fusco F; Galluzzi S; Hensch T; Jovicich J; Marra C; Molinuevo JL; Nobili F; Parnetti L; Payoux P; Ranjeva JP; Ribaldi F; Rolandi E; Rossini PM; Salvatore M; Soricelli A; Tsolaki M; Visser PJ; Wiltfang J; Richardson JC; Bordet R; Blin O; Frisoni GB
    Neurobiol Aging; 2020 May; 89():55-62. PubMed ID: 32029236
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.
    Mattsson N; Cullen NC; Andreasson U; Zetterberg H; Blennow K
    JAMA Neurol; 2019 Jul; 76(7):791-799. PubMed ID: 31009028
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CSF ApoE predicts clinical progression in nondemented APOEε4 carriers.
    van Harten AC; Jongbloed W; Teunissen CE; Scheltens P; Veerhuis R; van der Flier WM
    Neurobiol Aging; 2017 Sep; 57():186-194. PubMed ID: 28571653
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential Signaling Mediated by ApoE2, ApoE3, and ApoE4 in Human Neurons Parallels Alzheimer's Disease Risk.
    Huang YA; Zhou B; Nabet AM; Wernig M; Südhof TC
    J Neurosci; 2019 Sep; 39(37):7408-7427. PubMed ID: 31331998
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plasma biomarkers associated with the apolipoprotein E genotype and Alzheimer disease.
    Soares HD; Potter WZ; Pickering E; Kuhn M; Immermann FW; Shera DM; Ferm M; Dean RA; Simon AJ; Swenson F; Siuciak JA; Kaplow J; Thambisetty M; Zagouras P; Koroshetz WJ; Wan HI; Trojanowski JQ; Shaw LM;
    Arch Neurol; 2012 Oct; 69(10):1310-7. PubMed ID: 22801723
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Progression from MCI to AD: predictive value of CSF Aβ42 is modified by APOE genotype.
    Kester MI; Verwey NA; van Elk EJ; Blankenstein MA; Scheltens P; van der Flier WM
    Neurobiol Aging; 2011 Aug; 32(8):1372-8. PubMed ID: 19748159
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association between butyrylcholinesterase and cerebrospinal fluid biomarkers in Alzheimer's disease patients.
    Gabriel AJ; Almeida MR; Ribeiro MH; Durães J; Tábuas-Pereira M; Pinheiro AC; Pascoal R; Santana I; Baldeiras I
    Neurosci Lett; 2017 Feb; 641():101-106. PubMed ID: 28108398
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CSF biomarkers in Alzheimer's disease and controls: associations with APOE genotype are modified by age.
    Kester MI; Blankenstein MA; Bouwman FH; van Elk EJ; Scheltens P; van der Flier WM
    J Alzheimers Dis; 2009; 16(3):601-7. PubMed ID: 19276554
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Progression to dementia in memory clinic patients with mild cognitive impairment and normal β-amyloid.
    Rosenberg A; Solomon A; Jelic V; Hagman G; Bogdanovic N; Kivipelto M
    Alzheimers Res Ther; 2019 Dec; 11(1):99. PubMed ID: 31805990
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.
    Sunderland T; Mirza N; Putnam KT; Linker G; Bhupali D; Durham R; Soares H; Kimmel L; Friedman D; Bergeson J; Csako G; Levy JA; Bartko JJ; Cohen RM
    Biol Psychiatry; 2004 Nov; 56(9):670-6. PubMed ID: 15522251
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Apolipoprotein E imbalance in the cerebrospinal fluid of Alzheimer's disease patients.
    Lennol MP; Sánchez-Domínguez I; Cuchillo-Ibañez I; Camporesi E; Brinkmalm G; Alcolea D; Fortea J; Lleó A; Soria G; Aguado F; Zetterberg H; Blennow K; Sáez-Valero J
    Alzheimers Res Ther; 2022 Nov; 14(1):161. PubMed ID: 36324176
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plasma apolipoprotein E and Alzheimer disease risk: the AIBL study of aging.
    Gupta VB; Laws SM; Villemagne VL; Ames D; Bush AI; Ellis KA; Lui JK; Masters C; Rowe CC; Szoeke C; Taddei K; Martins RN;
    Neurology; 2011 Mar; 76(12):1091-8. PubMed ID: 21422459
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discordant amyloid-β PET and CSF biomarkers and its clinical consequences.
    de Wilde A; Reimand J; Teunissen CE; Zwan M; Windhorst AD; Boellaard R; van der Flier WM; Scheltens P; van Berckel BNM; Bouwman F; Ossenkoppele R
    Alzheimers Res Ther; 2019 Sep; 11(1):78. PubMed ID: 31511058
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Apolipoprotein E genotype is not associated with cognitive impairment in older adults with bipolar disorder.
    Kerr DS; Stella F; Radanovic M; Aprahamian I; Bertollucci PH; Forlenza OV
    Bipolar Disord; 2016 Feb; 18(1):71-7. PubMed ID: 26877211
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.